-

Facet Life Sciences Appoints Frank A. Closurdo as VP, Commercial Services, Strengthening Integrated Regulatory and Market Guidance

WAYNE, Pa.--(BUSINESS WIRE)--Facet Life Sciences, a product pathmaker for emerging biotechnology and pharmaceutical companies, today announced the appointment of Frank A. Closurdo as Vice President, Commercial Services. This addition marks a significant step forward in Facet’s continued expansion of its integrated regulatory and commercial advisory capabilities.

Facet Life Sciences, a product pathmaker for emerging biotechnology and pharmaceutical companies, today announced the appointment of Frank A. Closurdo as Vice President, Commercial Services.

Share

Closurdo brings more than two decades of experience spanning biopharmaceuticals, medical devices, and healthcare marketing, with leadership roles across both global organizations and early-stage companies. He has a proven track record of developing evidence-based commercial strategies and guiding successful product launches, acquisitions, and licensing across highly regulated, competitive markets.

“I am thrilled to have a seasoned professional like Frank join the Facet team,” said Ken VanLuvanee, Facet’s CEO & Board Chairman. “His years of successful consulting, deep understanding of how to turn a scientific concept into a market product, and familiarity with the needs of emerging life sciences companies, Facet's core constituency, will be a huge win for our clients."

In his new role, Closurdo will focus on leveraging commercial strategy earlier in the development lifecycle to maximize product value and support successful patient outcomes. In collaboration with Facet’s dedicated regulatory strategy experts, he will ensure that clinical protocols, regulatory expectations, and market considerations are aligned from the outset.

This appointment reinforces Facet’s position as a partner to lean science teams seeking both regulatory success and commercial viability in an increasingly complex healthcare landscape.

About Facet Life Sciences
Facet Life Sciences supports emerging life sciences companies looking for feasible pathways to and through the FDA. With deep expertise across therapeutic applications, Facet provides regulatory strategy, FDA submission leadership, gap analysis, regulatory writing services, commercial strategy, and more. The multidisciplinary team of experts helps innovators navigate regulatory complexity and build cost-conscious programs designed for both FDA approval and real-world success.

Follow Facet Life Sciences on LinkedIn: linkedin.com/company/facet-life-sciences

Contacts

Tom Hallam, Ph.D., MBA
President & COO
tom.hallam@facetls.com

Facet Life Sciences


Release Summary
Facet Life Sciences, a product pathmaker for emerging biotech and pharmaceutical companies, announced Frank Closurdo as VP, Commercial Services.
Release Versions

Contacts

Tom Hallam, Ph.D., MBA
President & COO
tom.hallam@facetls.com

Social Media Profiles
More News From Facet Life Sciences

Facet Life Sciences Evolves Leadership Structure to Strengthen Product Pathmaking Solutions & Deepen Partnership Value

WAYNE, Pa.--(BUSINESS WIRE)--Facet Life Sciences, a product pathmaker for emerging biotechnology, pharmaceutical, and device developers, announced changes to its executive team....

Facet Life Sciences Publishes Second Edition of FDA and Intellectual Property Strategies for Medical Device Technologies

PHOENIXVILLE, Pa.--(BUSINESS WIRE)--Facet Life Sciences, a regulatory affairs and product development strategy partner, is proud to announce the release of the second edition of FDA and Intellectual Property Strategies for Medical Device Technologies, an updated resource for medical device innovators featuring six Facet Life Sciences experts as contributing authors. “The journey from medical device concept to commercialization has been significantly impacted by recent key shifts in the technolo...
Back to Newsroom